ZVRA
Zevra Therapeutics, Inc.
$11.13
+1.18%
2026-05-08
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Key Fundamentals
P/E Ratio
5.61
Forward P/E
6.77
EPS (TTM)
$2.01
ROE
85.7%
Revenue Growth (YoY)
183.4%
Profit Margin
78.2%
Debt/Equity
40.87
Price/Book
4.14
Beta
0.88
Market Cap
$666.2M
Avg Volume (10D)
1.2M
Recent Breakout Signals
No recent breakout signals detected for ZVRA.
Recent Price Range (60 Days)
60D High
$11.60
60D Low
$8.29
Avg Volume
1.1M
Latest Close
$11.13
Get breakout alerts for ZVRA
Sign up for Breakout Scanner to receive daily notifications when ZVRA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Zevra Therapeutics, Inc. (ZVRA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ZVRA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ZVRA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.